BRIACELL THERAPEUTICS CORP. Financing Cash Flow
BRIACELL THERAPEUTICS CORP. (BCTX) reported Financing Cash Flow of $27.87 million for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-06-09
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for the quarter ending 2026-04-30 was $0.00, a 100.00% decline year-over-year.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for the quarter ending 2025-07-31 was $13.56M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for the quarter ending 2025-04-30 was $14.71M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for the quarter ending 2025-01-31 was $5.22M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for fiscal 2025 was $45.45M, a 928.49% increase from fiscal 2024.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for fiscal 2024 was $4.42M, a 11.75% increase from fiscal 2023.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for fiscal 2023 was $3.95M.
- BRIACELL THERAPEUTICS CORP. net cash provided by (used in) financing activities for fiscal 2022 was -$3.74M, a 105.76% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $27.87M 10-Q · filed 2026-06-09 | ||
| 2026-01-31 | $27.87M 10-Q · filed 2026-03-10 | |||
| 2025-07-31 | $13.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16 | $28.27M derived: sum of 2 quarters · filed 2026-06-09 | $33.49M derived: sum of 3 quarters · filed 2026-06-09 | $45.45M 10-K · filed 2025-10-16 |
| 2025-04-30 | $14.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09 | $19.93M derived: sum of 2 quarters · filed 2026-06-09 | $31.89M 10-Q · filed 2026-06-09 | |
| 2025-01-31 | $5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10 | $17.18M 10-Q · filed 2026-03-10 | ||
| 2024-10-31 | $11.96M 10-Q · filed 2025-12-11 | |||
| 2024-07-31 | $4.42M 10-K · filed 2025-10-16 | |||
| 2023-07-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-10-29 | $4.00M derived: sum of 2 quarters · filed 2024-10-29 | $4.00M derived: sum of 3 quarters · filed 2024-10-29 | $3.95M 10-K · filed 2024-10-29 |
| 2023-04-30 | $1.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | $1.59K derived: sum of 2 quarters · filed 2024-06-14 | -$45.70K 10-Q · filed 2024-06-14 | -$205.48K derived: sum of 4 quarters · filed 2024-06-14 |
| 2023-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-18 | -$47.29K 10-Q · filed 2024-03-18 | -$207.08K derived: sum of 3 quarters · filed 2024-03-18 | $1.16M derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | -$47.29K 10-Q · filed 2023-12-14 | -$207.08K derived: sum of 2 quarters · filed 2023-12-14 | $1.16M derived: sum of 3 quarters · filed 2023-12-14 | |
| 2022-07-31 | -$159.78K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-25 | $1.21M derived: sum of 2 quarters · filed 2023-10-25 | -$3.74M 10-K · filed 2023-10-25 | |
| 2022-04-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-14 | -$3.58M 10-Q · filed 2023-06-14 | ||
| 2022-01-31 | -$4.95M 10-Q · filed 2023-03-16 | |||
| 2021-07-31 | $65.00M 10-K · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |